Takeda Pharmaceutical has acquired TiGenix, a Belgian developer of therapeutics from its platforms of allogeneic, or donor-derived, expanded stem cells for $628m. TiGenix becomes a wholly-owned​ subsidiary of Takeda. Ordinary Shares have been delisted from Euronext Brussels and Nasdaq. “We are excited about our future together, as well as the benefit we can provide to patients with GI disorders. As we look ahead, we are aiming to be fully integrated by the end of our fiscal year to ensure we can continue to build on the value we are providing to those with GI disorders as quickly and efficiently as possible.” Asit Parikh, Head of Takeda’s Gastroenterology Therapeutic Area Unit.